The distribution of the anticancer drug doxorubicin in relation to blood vessels in solid tumors

被引:378
作者
Primeau, AJ
Rendon, A
Hedley, D
Lilge, L
Tannock, IF
机构
[1] Princess Margaret Hosp, Div Appl Mol Oncol, Toronto, ON M5G 2M9, Canada
[2] Princess Margaret Hosp, Div Biophys & Bioimaging, Toronto, ON M4X 1K9, Canada
[3] Princess Margaret Hosp, Div Med Oncol & Hematol, Toronto, ON M4X 1K9, Canada
[4] Univ Toronto, Toronto, ON, Canada
关键词
D O I
10.1158/1078-0432.CCR-05-1664
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Anticancer drugs gain access to solid tumors via the circulatory system and must penetrate the tissue to kill cancer cells. Here, we study the distribution of doxorubicin in relation to blood vessels and regions of hypoxia in solid tumors of mice. Experimental Design:The distribution of doxorubicin was quantified by immunofluorescence in relation to blood vessels (recognized by CD31) of murine 16C and EMT6 tumors and human prostate cancer PC-3 xenografts. Hypoxic regions were identified by injection of EF5. Results: The concentration of doxorubicin decreases exponentially with distance from tumor blood vessels, decreasing to half its perivascular concentration at a distance of about 40 to 50 gm, The mean distance from blood vessels to regions of hypoxia is 90 to 140 mu m in these tumors. Many viable tumor cells are not exposed to detectable concentrations of drug following a single injection. Conclusions: Limited distribution of doxorubicin in solid tumors is an important and neglected cause of clinical resistance that is amenable to modification. The technique described here can be adapted to studying the distribution of other drugs within solid tumors and the effect of strategies to modify their distribution.
引用
收藏
页码:8782 / 8788
页数:7
相关论文
共 21 条
[1]   COMPARATIVE ACTIVITY OF DOXORUBICIN AND ITS MAJOR METABOLITE, DOXORUBICINOL, ON V79/AP4 FIBROBLASTS - A MORPHOFUNCTIONAL STUDY [J].
BERNARDINI, N ;
GIANNESSI, F ;
BIANCHI, F ;
DOLFI, A ;
LUPETTI, M ;
ZACCARO, L ;
MALVALDI, G ;
DELTACCA, M .
EXPERIMENTAL AND MOLECULAR PATHOLOGY, 1991, 55 (03) :238-250
[2]  
Davis A J, 2000, Lancet Oncol, V1, P86, DOI 10.1016/S1470-2045(00)00019-X
[3]   Advanced microscopy solutions for monitoring the kinetics and dynamics of drug-DNA targeting in living cells [J].
Errington, RJ ;
Ameer-beg, SM ;
Vojnovic, B ;
Patterson, LH ;
Zloh, M ;
Smith, PJ .
ADVANCED DRUG DELIVERY REVIEWS, 2005, 57 (01) :153-167
[4]   An experimental and mathematical model for the extravascular transport of a DNA intercalator in tumours [J].
Hicks, KO ;
Ohms, SJ ;
vanZijl, PL ;
Denny, WA ;
Hunter, PJ ;
Wilson, WR .
BRITISH JOURNAL OF CANCER, 1997, 76 (07) :894-903
[5]   Microregional effects of gemcitabine in HCT-116 xenografts [J].
Huxham, LA ;
Kyle, AH ;
Baker, JHE ;
Nykilchuk, LK ;
Minchinton, AI .
CANCER RESEARCH, 2004, 64 (18) :6537-6541
[6]   The next frontier of molecular medicine: Delivery of therapeutics [J].
Jain, RK .
NATURE MEDICINE, 1998, 4 (06) :655-657
[7]   Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy [J].
Jain, RK .
SCIENCE, 2005, 307 (5706) :58-62
[8]  
Kerbel R S, 1996, Hum Cell, V9, P257
[9]   Repopulation of cancer cells during therapy: An important cause of treatment failure [J].
Kim, JJ ;
Tannock, IF .
NATURE REVIEWS CANCER, 2005, 5 (07) :516-525
[10]  
Lankelma J, 1999, CLIN CANCER RES, V5, P1703